{
  "id": 18643626,
  "title": "Diwali shagun ke shares! Angel One selects 8 stocks with up to 50% upside to Buy this Diwali. How many do you own?",
  "url": "https://urgent.news/2026/11/07/diwali-shagun-ke-shares-angel-one-selects-8-stocks-with-up-to-50",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-07T04:48:54.000Z",
  "source": {
    "name": "The Economic Times - Top News",
    "slug": "the-economic-times-top-news",
    "url": "https://economictimes.indiatimes.com/markets/stocks/news/diwali-shagun-ke-shares-angel-one-selects-8-stocks-with-up-to-50-upside-to-buy-this-diwali-how-many-do-you-own/festive-picks/slideshow/135626837.cms"
  },
  "original_language": "en",
  "account": "As the year 2083 begins, investors face the need for discernment over impulsive enthusiasm. Global uncertainties, shifting capital flows and evolving market expectations continue to impact equity performance. Sustainable wealth creation is expected to rely more on pinpointing businesses capable of steady earnings growth rather than on overall market trends. Angel One, a brokerage, has identified eight stocks it anticipates to appreciate substantially this Diwali. The brokerage has set a target price of Rs 1,800 for State Bank of India, indicating a potential 14.5% increase from the current market value. This private lender is India's second largest private-sector bank, boasting a market capitalization of approximately Rs 10 lakh crore and a widespread presence in retail, small and medium enterprise (SME) and corporate sectors. Another stock Angel One is bullish on is Tata Elxsi, a software and IT services company with a target price of Rs 330 per share, signifying a 16% upside. The company is optimistic, given a 6.1x estimated earnings per share (EPS) of Rs 54, which is roughly equal to the stock's book value; the stock trades at a price 4.5 times its earnings. Angel One also identifies Aarti Pharmalabs as a promising investment, with a target price of Rs 1,160, representing a 25% upside. The company is India's largest manufacturer of xanthine derivatives, holding a 15-20% global market share. Its manufacturing process is self-sufficient, with minimal reliance on imports from China. Shanti is also seen as a potential growth stock, with a target price of Rs 410, indicating a 50% increase from its present level. The company has the potential for consistent volume growth, as new manufacturing facilities and retail customers are projected to contribute to a 50-60% revenue growth in FY27. Lastly, BHEL is a 10% upside target price, suggesting a potential 10% rise from current levels. Analysts anticipate earnings growth as the company expands its consultancy services, backed by a Rs 14,424 crore order book and a revenue target of Rs 5,000 crore for FY28. Disclosure: The author of this article, Veer Sharma, is neither a SEBI-registered Research Analyst nor an Investment Adviser. Sharma and his relatives do not hold any financial stake in the companies mentioned in this article as of the publication date. The views and recommendations expressed in this article are those of the respective SEBI-registered Research Analyst/brokerage and have been reported with appropriate attribution. They should not be viewed as the opinions or recommendations of The Economic Times Digital or the journalist. Investors are advised to evaluate the original research report and make their investment decisions based on their own assessment.",
  "summary": "As investors enter Samvat 2083, the landscape calls for selectivity rather than indiscriminate optimism. Global uncertainties, fluctuating capital flows and evolving market expectations continue to influence equity performance. In this environment, sustainable wealth creation is likely to depend less on broad-based market movements and more on identifying businesses capable of delivering…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}